INTERCEPT PHARMACEUTICALS, INC. (ICPT) Class Action Lawsuit (September 2017)
Closed20-3488 • September 27, 2017
Class Period Start
June 9, 2016
Class Period End
September 20, 2017
PSLRA Deadline
November 27, 2017
Case Allegations
10b5
Statutes of Repose
Jun 9, 2019
Country
United States
Court
Federal Court
Docket History
Jul 20, 2022
Oct 9, 2020
Mar 27, 2020
Motion to Dismiss Granted (opens in a new tab)
The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.
Oct 18, 2018
Sep 14, 2018
Motion to Dismiss (opens in a new tab)
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Jul 31, 2018
First Amended Complaint (opens in a new tab)
A new complaint has been filed on behalf of certain investors in INTERCEPT PHARMACEUTICALS, INC.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Jun 1, 2018
Appointment of Lead Plaintiff (opens in a new tab)
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Jan 3, 2018
Sep 27, 2017
First Filed Complaint (opens in a new tab)
A securities fraud class action complaint has been filed on behalf of certain investors in INTERCEPT PHARMACEUTICALS, INC..